Multidrug resistance phenotype in the RMS-GR human rhabdomyosarcoma cell line obtained after polychemotherapy

Japanese Journal of Cancer Research

Volumn 90, Issue 7, 1999, Pages 788-793

  Prados, Jose ^a   Melguizo, Consolación ^a   Marchal, Juan Antonio ^b   Vélez, Celia ^a   Alvarez, Luis ^c   Aránega, Antonia ^c  

^a UNIVERSITY OF ALMERÍA   (Spain)

^b UNIVERSITY OF JAÉN   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

mdr1; Multidrug resistance; P glycoprotein; Rhabdomyosarcoma

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE;

ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS RESISTANCE; EMBRYONAL RHABDOMYOSARCOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0032804555     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00816.x     Document Type: Article

References (33)

1. Lehnert, M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur. J. Cancer, 32, 912-920 (1996).
2. Vergier, B., Cany, L., Bonnet, F., Robert, J., De Mascarel, A. and Coindre, J. M. Expression of MDR/P-glycoprotein in human sarcomas. Br. J. Cancer, 68, 1221-1226 (1993).
3. Harrison, D. J. Molecular mechanisms of drug resistance in tumours. J. Pathol., 175, 7-12 (1995).
4. Nooter, K. and Herweijer, H. Multidrug resistance (mdr) genes in human cancer. Br. J. Cancer, 63, 663-669 (1991).
5. German, U. A. P-Glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer, 32, 927-944 (1996).
6. Pappo, A. S. Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr. Opin. Oncol., 7, 361-366 (1995).
7. Harm, D. New entities, concepts, and questions in childhood tumor pathology. Gen. Diagn. Pathol., 141, 1-141 (1995).
8. Waxman, S., Borden, E. C., Lotam, R., Levens, D. and Young, C. W. Differentiation therapy of cancer: laboratory and clinical investigations. Cancer Res., 53, 4109-4115 (1993).
9. Molenaar, W. M., Oosterhuis, J. W. and Kamps, W. A. Cytologic differentation in childhood rhabdomyosarcoma following polychemotherapy. Hum. Pathol., 15, 973-979 (1984).
10. d'Amore, E. S. G., Tollot, M., Straca-Pansa, V., Menegon, A., Mell, S., Carli, M. and Ninfo, V. Therapy associated differentiation in rhabdomyosarcomas. Mod. Pathol., 7, 69-75 (1994).
11. Melguizo, C., Prados, J., Fernández, J. E., Vélez, C., Alvarez, L. and Aránega, A. Differentiation of a human rhabdomyosarcoma cell line after antineoplastic drug treatment. J. Pathol., 175, 23-29 (1995).
12. Kaye, S. B. P-Glycoprotein and drug resistance - time for reappraisal? Br. J. Cancer, 67, 641-643 (1993).
13. Fernández, J. E., Prados, J., Melguizo, C., Arena, N., Malavasi, F., Álvarez, L. and Aránega, A. Characterization of a new human embryonal rhabdomyosarcoma cell line, RMS-GR. Jpn. J. Cancer Res., 89, 525-532 (1998).
14. Prados, J., Melguizo, C., Marchal, J. A., Velez, C., Alvarez, L. and Aránega, A. Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D. Int. J. Cancer, 75, 379-383 (1998).
15. Maniatis, T., Fristch, E. and Sambrook, J. "Molecular Cloning, A Laboratory Manual" (1982). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
16. Fuqua, S. A. W., Fitzgerald, S. D. and McGuire, W. L. A simple polymerase chain reaction method for detection and cloning of low-abundance transcripts. Biotechniques, 9, 206-211 (1990).
17. Wu, L., Smythe, A. M., Stinson, S. F., Mullendore, L. A., Monks, A., Scudeiro, D. A., Paull, K. D., Koutsoukos, A. D., Rubinstein, L. V., Boyd, R. B. and Shoemaker, R. H. Multidrug-resistance phenotype of disease-oriented panels of human tumor cell line used for anticancer drug screening. Cancer Rex., 52, 3029-3034 (1992).
18. Scheper, R. J., Bulte, J. W. M., Brakkee, J. G. P., Quak, J. J., Van der Schoot, E., Balm, A. J. M., Meuer, C. J., Broxterman, H. J., Kuiper, C. M., Lankelma, J. and Pinedo, H. N. Monoclonal antibody JSB-I detects a highly conserved epitope on the P-glycoprotein associated with multidrug-resistance. Int. J. Cancer, 42, 389-394 (1988).
19. Fisher, G. A., Lum, B. L., Hausdorff, J. and Sikic, B. I. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer, 32, 1082-1088 (1996).
20. Boiocchi, M. and Toffoli, G. Mechanism of multidrug resistance in human tumour cell lines and complete reversion of cellular resistance. Eur. J. Cancer, 28, 1099-1105 (1992).
21. Thisler, D. M. and Raffel, C. Development of multidrug resistance in a primitive neuroectodermal tumor cell line. J. Neurosurg., 76, 502-506 (1992).
22. Van de Vrie, W., Marqurt, R. L., Stoter, G., De Bruijn, E. A. and Eggermont, A. M. In vivo model systems in P-glycoprotein-mediated multidrug resistance. Crit. Rev. Clin. Lab. Sci., 35, 1-57 (1998).
23. Loe, D. W., Deeley, R. G. and Cole, S. P. C. Biology of the multidrug resistance-associated protein, MRP. Eur. J. Cancer. 32, 927-944 (1996).
24. Volm, M. Multidrug resistance and its reversal. Anticancer Res., 18, 2905-2917 (1998).
25. Baggetto, L. G. Biochemical, genetic and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies. J. Bioenerg. Biomembr., 29, 401-413 (1997).
26. Golstein, L. J. MDRI gene expression in solid tumours. Eur. J. Cancer, 32, 1039-1050 (1996).
27. Garberoglio, C., Dudas, M., Casper, E. S., Bertino, J. and Cordon-Cardo, C. Expression of P-glycoprotein in normal muscle cells and myogenic tumors. Arch. Pathol. Lab. Med., 116, 1055-1061 (1992).
28. Chan, H. S., DeBoer, G., Thorner, P. S., Haddad, G., Gallie, B. L. and Ling, V. Multidrug resistance. Clinical opportunities in diagnosis and circumvention. Hematol. Oncol. Clin. North Am., 8, 383-410 (1994).
29. Kellen, J. A. Molecular interrelationships in multidrug resistance. Anticancer Res., 14, 433-435 (1994).
30. Prados, J., Melguizo, C., Fernández, J. E., Aránega, A. E., Alvarez, L. and Aránega, A. Inverse expression of mdr1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin D. J. Pathol., 180, 85-89 (1996).
31. Melguizo, C., Prados. J., Marchal, J. A., Aranega, A. E., Alvarez, L. and Aránega, A. Low concentrations of actinomycin D cause potentially therapeutic differentiation in human rhabdomyosarcoma cell line RD. Pathol. Res. Pract., 192, 188-194 (1996).
32. Beck, W. T. and Danks, M. K. Multidrug resistance in tumor cells. In "Molecular and Cellular Biology," ed. I. B. Roninson, pp. 3-46 (1991). Plenum Publ. Corp., New York.
33. Brown, R. Gene amplification and drug resistance J. Pathol., 69, 287-292 (1991).